The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial

The present study aims to investigate the effects of the combined therapy myo-inositol (MI) plus d-chiro-inositol (DCI) or d-chiro-inositol treatment in oocyte quality. Polycystic ovary syndrome (PCOS) women undergoing IVF-ET were treated with myo-inositol combined with d-chiro-inositol in the physiological ratio (1.1 g myo-inositol plus 27.6 mg of d-chiro-inositol; INOFOLICA (R) combi Lo.Li.pharma) or d-chiro-inositol alone (500 mg; Interquim, s.a., Barcelona, Spain) to evaluate the umber of morphological mature oocytes, total International Units (IU) of recombinant FSH administered and the number of grade 1 embryos. The data clearly showed that only the combined therapy was able to improve oocyte and embryo quality, as well as pregnancy rates, in PCOS women undergoing IVF-ET. The present paper further supports the hypothesis that MI plays a crucial role in the ovary in PCOS women. In particular, due to the physiological role played by MI and DCI, the combined therapy should represent a better choice.